Sleep problems are nearly universal in children with ADHD, autism, and chronic illness—but how much can behavioral interventions actually move the needle? A meta-analysis of 15 RCTs examines what changes, what doesn't, and whether the gains last.

Treatment access for adolescent mental health and substance use isn't keeping pace with rising rates. A national survey of over 32,000 youth reveals just how wide the gaps are and why turning 18 may make things measurably worse.

NMS is feared but poorly characterized in pediatric populations. A Medicaid cohort of 1.66 million young antipsychotic users now offers the clearest picture yet of when risk is highest and which combinations clinicians should watch most closely.

Irritability in pediatric ADHD often persists despite stimulant treatment, yet targeted options are limited. Could an NMDA antagonist already sitting on pharmacy shelves offer a safer adjunct? A small pilot trial reports a striking early signal.

Not all studies are created equal — and in child psychiatry, the stakes of getting it wrong are high. Dr. Spielmans introduces the PICOT framework, exposes common sources of bias in clinical trials, and offers practical tools for vetting the research before it reaches your patients.

SSRIs are standard for pediatric OCD, but how much do they actually move the needle? An individual participant data meta-analysis puts a number on it, and the answer is more nuanced than the guidelines suggest. Baseline severity, it turns out, matters more than most clinicians realize.

After reading these articles, you should be able to…